Cellenkos is a clinical-stage biotechnology company focused on developing universal donor cell therapeutics derived from cord blood for the treatment of autoimmune diseases and inflammatory conditions.
Cellenkos manufacturing facility (CMF) manufactures cord blood-derived Treg therapeutics. CMF covers 2,000 square feet and includes a Class 10,000 (corresponding to International Organization for Standardization 7) cleanroom with gown-in/gown-out anteroom where all major equipment will remain under continuous monitoring with off-site data backup.
All preclinical research and development, as well as clinical manufacturing and packaging of clinical product will take place at CMF.
It is anticipated that CMF will have the capacity to supply sufficient quantities of Cellenkos' lead cellular therapy candidate, CK0801, for all company-sponsored clinical trials.
Cellenkos is an early stage biotechnology company that focuses on Treg cellular therapies derived from cord blood for the treatment of autoimmune diseases and inflammatory disorders. Cellenkos' lead product, CK0801, is a first-in-class, cell therapy product that overcomes immune dysfunction by inhibiting key regulators of inflammation.
Golden Meditech is an integrated-healthcare enterprise that has established dominant positions in several markets, including the medical devices market and the hospital management market in the healthcare industry.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML